KMS Medisurgi Ltd

KMS Medisurgi Ltd has submitted standalone audited financial results for the year ended March 31, 2026, as per SEBI regulations. The board approved the results along with the Independent Auditors' Report, which includes a qualified opinion due to concerns regarding Post-Employment Benefits accounting and stock record reconciliation. The auditor's report mentions a qualified opinion due to deviations from AS-15 and pending stock reconciliation of ₹253.80 Lacs.

KMS Medisurgi Ltd has submitted its standalone audited financial results for the year ended March 31, 2026, as per SEBI regulations. The board approved the results along with the Independent Auditors Report, which includes a qualified opinion due to concerns regarding Post-Employment Benefits and stock records. The auditor's qualified opinion highlights a departure from AS-15 on Employee Benefits due to the lack of an actuarial report for Post-Employment Benefits and other long-term employee benefits. Additionally, the company is in the process of reconciling stock records, with a closing stock valued at ₹253.80 Lacs.

KMS Medisurgi Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the standalone audited financial results for the year ended March 31, 2026. The meeting will take place at the company's registered office in Mumbai. The trading window for dealing in the company's equity shares has been closed since April 1, 2026, and will remain closed until 48 hours after the financial results are communicated to the Stock Exchange.

A meeting of the Board of Directors of KMS Medisurgi Limited will be held on Saturday, May 30, 2026, at 02.00 pm at the registered office of the company. The board will consider and approve the standalone audited financial results for the year ended March 31, 2026. The trading window has been closed from April 01, 2026 and will remain closed until 48 hours after the financial results are communicated to the stock exchange.

Mr. Pratik Pravin Tarpara has ceased to be an Independent Director of KMS Medisurgi Ltd effective September 30, 2025, upon completion of his tenure. This follows Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company acknowledged his contributions during his term. Details regarding the cessation are provided in Annexure A as per SEBI guidelines.

KMS Medisurgi Ltd announced that Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates an Annual Secretarial Compliance Report, is not applicable to the company. This exemption is granted under Regulation 15(2) of SEBI (LODR) Regulations, 2015, because the company is listed on the BSE SME Platform. Consequently, KMS Medisurgi is not required to submit the Annual Secretarial Compliance Report.

KMS Medisurgi Ltd has announced its exemption from submitting the Corporate Governance Report as per Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This non-applicability stems from the company's listing on the BSE SME Platform, which qualifies it under Regulation 15(2) of the same regulations. Consequently, KMS Medisurgi is not required to disclose the Report on Corporate Governance for the year ended March 31, 2026.

KMS Medisurgi Ltd, with scrip code 540468, has announced the closure of its trading window. This closure will be in effect from 1st April 2026 until 48 hours after the announcement of the Audited Financial Results for the half year and year ended 31st March 2026. This move is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

KMS Medisurgi Ltd, a company listed on the BSE SME Platform, has announced that it is exempted from the compliance with the corporate governance provisions as specified in regulations 17, 17A, 18, 19, 20, 21,22, 23, 24, 24A, 25, 26, 27 and clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V. This exemption is due to the company's paid up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty five crore, as on the last day of the previous financial year. Consequently, the company is not required to disclose Report on Corporate Governance pursuant to Regulation 27 (2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 for the Quarter ended 31° December, 2025.

KMS Medisurgi Ltd has reported its unaudited standalone financial results for the half year ended on September 30, 2025. The company's revenue from operations stands at ₹ 661.66 crore, with a profit before tax of ₹ 25.63 crore. The company has commenced maintaining certain stock records for material items from the previous year and is in the process of reconciling these stock records with the books of accounts. The closing stock as on half year ended September 30, 2025 has been physically verified and valued by the management.